Effect of Shugan Hezhong Decoction in treatment of patients with diarrhea-predominant irritable bowel syndrome differentiated as liver depression and spleen deficiency syndrome

WANG Kejian; YANG Qin

doi:10.7619/jcmp.20213488

Journal of Clinical Medicine in Practice > 2021 > 25(23): 58-61, 68. > DOI: 10.7619/jcmp.20213488

WANG Kejian, YANG Qin. Effect of Shugan Hezhong Decoction in treatment of patients with diarrhea-predominant irritable bowel syndrome differentiated as liver depression and spleen deficiency syndrome[J]. Journal of Clinical Medicine in Practice, 2021, 25(23): 58-61, 68. DOI: 10.7619/jcmp.20213488

Citation:

PDF (747 KB)

Effect of Shugan Hezhong Decoction in treatment of patients with diarrhea-predominant irritable bowel syndrome differentiated as liver depression and spleen deficiency syndrome

WANG Kejian,
YANG Qin^,

Nanjing Hospital of Traditional Chinese Medicine Affiliated to Nanjing Universityof Traditional Chinese Medicine, Nanjing, Jiangsu, 210001

More Information

Received Date: August 29, 2021
Available Online: December 05, 2021
Published Date: December 14, 2021

Graphical Abstract

Abstract

Abstract

Objective To observe the clinical effect of Shugan Hezhong Decoction in the treatment of patients with diarrhea-predominant irritable bowel syndrome (IBS-D) differentiated as liver depression and spleen deficiency syndrome.
Methods Totally 64 patients who met the diagnostic criteria of IBS-D differentiated as liver depression and spleen deficiency syndrome in Nanjing City Hospital of Traditional Chinese Medicine from March 2020 to March 2021 were selected and randomly divided into treatment group (treated with Shugan Hezhong Decoction) and control group (treated with live combined bacillus subtilis and enterococcus faecium enteric-coated capsules), with 32 cases in each group. After 4 weeks of treatment, the clinical symptom score and curative effect were evaluated in both groups.
Results After treatment, the main symptom score, secondary symptom score and total symptom score in both groups were significantly lower than those before treatment, and the main symptom score and total symptom score of the treatment group were significantly lower than those of the control group (P < 0.05). After treatment, the single symptom scores in both groups reduced significantly, and the single symptom scores of abdominal pain, stool shapes and properties, irritability, chest tightness and sigh and abdominal distension in the treatment group were significantly lower than those in the control group (P < 0.05). After treatment, the total effective rate in the treatment group was 93.75%, which was significantly higher than 68.75% in the control group (P < 0.05).
Conclusion Shugan Hezhong Decoction can effectively alleviate the gastrointestinal symptoms of patients with IBS-D differentiated as liver depression and spleen deficiency syndrome, enhance the treatment effect and improve the qualities of life of patients.

FullText(HTML)

References (27)

References

[1]	RAJILIC-STOJANOVIC M, JONKERS D M, SALONEN A, et al. Intestinal microbiota and diet in IBS: causes, consequences, or epiphenomena[J]. Am J Gastroenterol, 2015, 110(2): 278-287. doi: 10.1038/ajg.2014.427
[2]	陈懿榕, 林柳兵, 李勇. 腹泻型肠易激综合征中西医研究进展探微[J]. 现代中西医结合杂志, 2019, 28(22): 2496-2500. doi: 10.3969/j.issn.1008-8849.2019.22.027
[3]	李军祥, 陈誩, 唐旭东, 等. 肠易激综合征中西医结合诊疗共识意见(2017年)[J]. 中国中西医结合消化杂志, 2018, 26(3): 227-233.
[4]	张声生, 魏玮, 杨俭勤. 肠易激综合征中医诊疗专家共识意见(2017)[J]. 中医杂志, 2017, 58(18): 1614-1620.
[5]	郑筱萸. 中药新药临床研究指导原则: 试行[M]. 北京: 中国医药科技出版社, 2002: 11-15.
[6]	林三仁. 消化内科学高级教程[M]. 北京: 人民军医出版社, 2009: 33-41.
[7]	王子恺, 杨云生. 感染后肠易激综合征[J]. 胃肠病学和肝病学杂志, 2012, 21(10): 966-970.
[8]	李宁宁, 方秀才. 脑-肠轴在肠易激综合征发病中的作用[J]. 胃肠病学和肝病学杂志, 2013, 22(2): 163-166.
[9]	宁丽琴, 叶柏. 肠易激综合征研究进展[J]. 现代医学, 2008, 36(6): 449-452.
[10]	张磊. EphrinB2/ephB2调节ENS突触可塑性参与IBS内脏高敏感的机制研究[D]. 武汉: 华中科技大学, 2017.
[11]	SU J, TANAKA Y, MURATSUBAKI T, et al. Injection of corticotropin-releasing hormone into the amygdala aggravates visceral nociception and induces noradrenaline release in rats[J]. Neurogastroenterol Motil, 2015, 27(1): 30-39. doi: 10.1111/nmo.12462
[12]	贺延新, 刘琳琳, 王东明. 肠易激综合征与精神心理因素相关性的分析及研究[J]. 中国继续医学教育, 2017, 9(3): 84-86. doi: 10.3969/j.issn.1674-9308.2017.03.047
[13]	FACHI J L, FELIPE J S, PRAL L P, et al. Butyrate protects mice from Clostridium difficile-induced colitis through an HIF-1-dependent mechanism[J]. Cell Rep, 2019, 27(3): 750-761, e7. doi: 10.1016/j.celrep.2019.03.054
[14]	AKBAR A, YIANGOU Y, FACER P, et al. Increased capsaicin receptor TRPV1-expressing sensory fibres in irritable bowel syndrome and their correlation with abdominal pain[J]. Gut, 2008, 57(7): 923-929. doi: 10.1136/gut.2007.138982
[15]	HAN W, WANG Z, LU X, et al. Protease activated receptor 4 status of mast cells in post infectious irritable bowel syndrome[J]. Neurogastroenterol Motil, 2012, 24(2): 113-9, e82. doi: 10.1111/j.1365-2982.2011.01841.x
[16]	FOND G, LOUNDOU A, HAMDANI N, et al. Anxiety and depression comorbidities in irritable bowel syndrome (IBS): a systematic review and meta-analysis[J]. Eur Arch Psychiatry Clin Neurosci, 2014, 264(8): 651-660. doi: 10.1007/s00406-014-0502-z
[17]	JANSSENS K A, ZIJLEMA W L, JOUSTRA M L, et al. Mood and anxiety disorders in chronic fatigue syndrome, fibromyalgia, and irritable bowel syndrome: results from the LifeLines cohort study[J]. Psychosom Med, 2015, 77(4): 449-457. doi: 10.1097/PSY.0000000000000161
[18]	KOVÁCS Z, KOVÁCS F. Depressive and anxiety symptoms, coping strategies in patients with irritable bowel syndrome and inflammatory bowel disease[J]. Psychiatr Hung, 2007, 22(3): 212-221.
[19]	吴寒, 张振玉. 肠易激综合征东西方指南对比解读[J]. 胃肠病学和肝病学杂志, 2019, 28(9): 961-967. doi: 10.3969/j.issn.1006-5709.2019.09.001
[20]	(明)张介宾, 孙玉信, 朱平生主校. 景岳全书[M]. 上海: 第二军医大学出版社, 2006: 1.
[21]	黄翌, 赵长鹰. 肠易激综合征从情志论治探讨[J]. 山东中医杂志, 2004, 23(10): 579-581. doi: 10.3969/j.issn.0257-358X.2004.10.001
[22]	李聪. 痛泻要方对内脏高敏性肠易激综合征大鼠模型作用及机制[J]. 创伤与急危重病医学, 2019, 7(2): 109-111, 117.
[23]	孙羽中, 潘伟娟, 陈富丽, 等. 痛泻要方对肠易激综合征肝郁脾虚证大鼠中枢神经系统SERT的影响[J]. 中华中医药学刊, 2019, 37(6): 1408-1411.
[24]	高耀, 李肖, 周玉枝, 等. 代谢组学在逍遥散抗抑郁药理研究中的应用[J]. 中草药, 2019, 50(14): 3453-3460. doi: 10.7501/j.issn.0253-2670.2019.14.028
[25]	王海燕, 邓素萍, 陈奕霞. 四逆散合痛泻要方加味对腹泻型肠易激综合征患者血清IL-1β及IL-8水平的影响[J]. 中国中医药科技, 2015, 22(5): 487-488.
[26]	岳竹君, 李冬华, 白霞. 肠易激综合征模型大鼠不同脑区核团c-fos的蛋白表达[J]. 时珍国医国药, 2012, 23(4): 857-858. doi: 10.3969/j.issn.1008-0805.2012.04.030
[27]	周晓凤, 王晓妍, 曹志群. 基于脑-肠轴探析肠易激综合征发病机制[J]. 山东中医药大学学报, 2021, 45(1): 68-71.

Cited By

Get Citation

PDF

XML

Article views (273) PDF downloads (13)

Turn off MathJax

Article Contents

Abstract

References

Effect of Shugan Hezhong Decoction in treatment of patients with diarrhea-predominant irritable bowel syndrome differentiated as liver depression and spleen deficiency syndrome

Abstract

References

Catalog

Export File

Citation

Format

Content